Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-004245
Filing Date
2025-02-14
Accepted
2025-02-14 18:12:35
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16060
2 JOINT FILING AGREEMENT ex-99-02142025_110233.htm EX-99.1 6890
  Complete submission text file 0001415889-25-004245.txt   24720
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Subject) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90885 | Film No.: 25631598
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A